HCL — vemurafenib plus rituximab holds promise
Crossref DOI link: https://doi.org/10.1038/s41571-021-00526-9
Published Online: 2021-05-24
Published Print: 2021-07
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Killock, David
Text and Data Mining valid from 2021-05-24
Version of Record valid from 2021-05-24
Article History
First Online: 24 May 2021